Oct 22
Merck & Co.'s third- quarter profit more than tripled as a gain from the sale of its stake in an animal-health joint venture masked the impact of generic competition on sales and continued weakness for the cholesterol drugs it sells jointly with merger partner Schering-Plough Corp. (SGP). But the drug maker's core results beat estimates, prompting it to boost the bottom end of its 2009 earnings target as it affirmed its revenue view. US Bancorp 3Q profit rises, bad loans increas
Leave a Reply
